ALZ-101 vs AV-1959R
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta · full Alzheimer's Disease pipeline
ALZ-101
Developed by Alzinova AB
NCT05328115 · Phase 1 · completed
Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.
Reported efficacy
Number of adverse events (AEs) and serious AEs (SAEs) (From enrolment through study completion, an average 1 year); Number of participants with treatment-emergent AEs and SAEs (From enrolment through study completion, an average 1 year); Number of AEs of special interest (AESIs), including injection-related events (IREs)and amyloid-related imaging abnormalities (ARIAs) (From enrolment through study completion, an average 1 year); Number of participants with clinically significant cognitive or functional worsening of Alzheimer's Disease(AD) according to Alzheimer's DiseaseCooperative Study -Clinician's Global Impression of Change (ADCS-CGIC)scores of 6 and 7 (From first dose to study completion, an average 1 year): Part A of the phase 1b trial of the anti-amyloid-oligomer vaccine ALZ-101 in early Alzheimer's disease: participants were randomised to receive placebo (n = 6), 125 micrograms (n = 10) or 250 micrograms (n = 10) of ALZ-101. The study met its primary and secondary endpoints, the vaccine was well tolerated, there were no cases of suspected meningoencephalitis or ARIA-E, and the vaccine proved immunogenic with oligomer-specific antibody titres evolving after three administrations. (met)
Result source: NCT05328115
AV-1959R
Developed by Nuravax, Inc.
NCT06831812 · Phase 1 · completed
The trial was randomized and blinded with a placebo comparator, but it enrolled only 16 people in total, with as few as two per placebo group, and it was designed to test safety and antibody response rather than a disease outcome. No serious adverse events occurred in any group, but the very small numbers mean the safety comparison cannot rule much out. Its registered primary outcome on ClinicalTrials.gov is "Safety and Tolerability of AV-1959R Compared to Placebo". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: October 2029 · NCT07827768 (registry estimate)
Reported efficacy
Safety and Tolerability of AV-1959R Compared to Placebo (Up to 26 weeks): Safety and Tolerability of AV-1959R Compared to Placebo (Up to 26 weeks): Arm 1: AV-1959R (100 µg) + Adjuvant - Cohort 1 — Participants with ≥1 TEAE: 5 Participants; Participants with ≥1 SAE: 0 Participants | Arm 2: Placebo (Adjuvant Only) - Cohort 1 — Participants with ≥1 TEAE: 1 Participants; Participants with ≥1 SAE: 0 Participants | Arm 3: AV-1959R (300 µg) + Adjuvant - Cohort 2 — Participants with ≥1 TEAE: 6 Participants; Participants with ≥1 SAE: 0 Participants | Arm 4: Placebo (Adjuvant Only) - Cohort 2 — Participants with ≥1 TEAE: 2 Participants; Participants with ≥1 SAE: 0 Participants (not_applicable)
Result source: NCT06831812
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALZ-101 | AV-1959R |
|---|---|---|
| CDR-SB, change | —Not reported | —Not reported |
| ADAS-Cog11, change | —Not reported | —Not reported |
| ADCS-ADL, change | —Not reported | —Not reported |
| MMSE, change | —Not reported | —Not reported |
| Amyloid PET, change (centiloids) | —Not reported | —Not reported |
CDR-SB, change
- ALZ-101
- —Not reported
- AV-1959R
- —Not reported
ADAS-Cog11, change
- ALZ-101
- —Not reported
- AV-1959R
- —Not reported
ADCS-ADL, change
- ALZ-101
- —Not reported
- AV-1959R
- —Not reported
MMSE, change
- ALZ-101
- —Not reported
- AV-1959R
- —Not reported
Amyloid PET, change (centiloids)
- ALZ-101
- —Not reported
- AV-1959R
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALZ-101: no structured comparison results are available for Alzheimer's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALZ-101: 0 of 4 rows · AV-1959R: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | AV-1959R |
|---|---|
| Dropout rate | 0%300 µg + Adjuvanta NCT06831812 · Phase 1 · combination show 1 more result0%100 µg + Adjuvant NCT06831812 · Phase 1 · combination |
| Discontinued due to AEs | —300 µg + Adjuvanta NCT06831812 · Phase 1 · combination show 1 more result—100 µg + Adjuvant NCT06831812 · Phase 1 · combination |
| Serious AEs | 0%300 µg + Adjuvanta NCT06831812 · Phase 1 · combination show 1 more result0%100 µg + Adjuvant NCT06831812 · Phase 1 · combination |
| Most frequent reported AEs | show 1 more result |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALZ-101's landscape · AV-1959R's landscape